CENTRE ANTOINE LACASSAGNE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1961-01-01
- Employees
- -
- Market Cap
- -
Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
Phase 1
Recruiting
- Conditions
- HER2 Negative Breast Cancer Not Immediately Operated
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 85
- Registration Number
- NCT05664893
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML
Phase 2
Recruiting
- Conditions
- AML
- Interventions
- Combination Product: Gemtuzumab ozogamicine - Cytarabine - Gilteritinib
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 50
- Registration Number
- NCT05199051
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Hôpital Lyon sud, Lyon, France
🇫🇷Hôpital la Timone Conception, Marseille, France
Virtual Reality for Children in Radiotherapy (REVER)
Not Applicable
Recruiting
- Conditions
- Virtual RealityPediatric CancerProton Therapy
- Interventions
- Procedure: Virtual reality
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 47
- Registration Number
- NCT04934293
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer
Phase 2
Recruiting
- Conditions
- Localized Breast Cancer
- Interventions
- Radiation: Per-Operative Radiotherapy technique by Papillon +TM
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 40
- Registration Number
- NCT04680715
- Locations
- 🇫🇷
Pôle Santé République, Clermont-Ferrand, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Thromboembolic Risk Screening in Patients With Cancer and COVID-19
Not Applicable
Completed
- Conditions
- Neoplasms MalignantThromboembolismCovid19
- Interventions
- Diagnostic Test: Peripheral venous ultrasound
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 88
- Registration Number
- NCT04616846
- Locations
- 🇫🇷
Clinique Saint-Jean, Cagnes-sur-Mer, Alpes-Maritimes, France
🇫🇷Clinique Saint-Georges, Nice, Alpes-Maritimes, France
🇫🇷CHU Nice, Nice, Alpes-Maritimes, France
COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID)
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Other: rapid serological test
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 214
- Registration Number
- NCT04492410
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
Study of the Impact of DPD Activity on the Efficacy of Capecitabine
Phase 2
Active, not recruiting
- Conditions
- Breast Neoplasm Malignant Female
- Interventions
- Other: DPD activity assessment
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 155
- Registration Number
- NCT04198727
- Locations
- 🇫🇷
Clinique Saint Jean, Cagnes-sur-Mer, France
🇫🇷Centre Azuréen de Cancérologie, Mougins, France
🇫🇷Clinique St Georges, Nice, France
Organoids From Metastases of Prostate Cancer
Not Applicable
Terminated
- Conditions
- Prostatic Neoplasm
- Interventions
- Other: extended biopsy
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 1
- Registration Number
- NCT03952793
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
THrombo-Embolic Event in Onco-hematology
Not Applicable
Completed
- Conditions
- ThrombosisCoagulation DisorderNeoplasms
- Interventions
- Diagnostic Test: Blood sample analysis
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 700
- Registration Number
- NCT03826043
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma
Not Applicable
Active, not recruiting
- Conditions
- Non-Small Cell Bronchopulmonary Carcinoma or Melanoma
- Interventions
- Radiation: 18FDG PET
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 100
- Registration Number
- NCT03584334
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
© Copyright 2025. All Rights Reserved by MedPath